Coherus Oncology CHRS
NASDAQ CHRS
$1.35 +0.02 (+1.89%)
As of: Sep 10, 2026 · 3:59 PM EDT

Coherus Oncology (CHRS) EPS (Diluted) (2015 - 2026)

Analysis

Coherus Oncology (CHRS) EPS (Diluted) (2015 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Diluted) (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 4.37
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn -8.44
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 4.31
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 12.23
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 7.15
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -1.96
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 1.19
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 0.66
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -0.40
10 Coherus Oncology 209.00 Mn 103.70 Mn 10.07 Mn -0.13
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -0.13
Mar 31, 2026 -0.28
Dec 31, 2025 -0.32
Sep 30, 2025 -0.31
Jun 30, 2025 2.57
Mar 31, 2025 -0.49
Dec 31, 2024 -0.44
Sep 30, 2024 -0.09
Jun 30, 2024 -0.11
Mar 31, 2024 0.82
Dec 31, 2023 -0.85
Sep 30, 2023 -0.41
Jun 30, 2023 -0.49
Mar 31, 2023 -0.96
Dec 31, 2022 -0.76
Sep 30, 2022 -1.11
Jun 30, 2022 -0.65
Mar 31, 2022 -1.24
Dec 31, 2021 -0.61
Sep 30, 2021 -0.49